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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: : Autophagy is important in cellular homeostasis and control of inflam-
matory immune response. Increased autophagy has recently been associated with increased
cell death and chronic obstructive pulmonary disease (COPD) pathogenesis. Two autophagy
regulator genes have been identified: Egr-1 (early growth response), associated with different
phenotype expressions in asthma; and, Atg16L1 (autophagy related 16-like 1), a candidate
gene responsible for susceptibility to chronic inflammatory diseases. We will explore the role
of the Egr-1 and Atg16L1 gene polymorphisms in COPD.
Methods: The genotypes of 151 male smoking patients with COPD and 100 male smoking con-
trols were evaluated by polymerase chain reaction followed by restriction fragment length
polymorphism analysis of the Egr-1 (e4071 A / G) rs7729723 and Atg16L-1 (T300A)
rs2241880 variants.
Results: The G allele of the Egr-1 gene polymorphism was associated with an increased risk of
developing COPD [odds ratio (OR), 2.05; 95% confidence interval (CI), 1.15e3.72], and partic-
ipants with the G allele polymorphism (GG and GA genotypes) had a 2.56-fold higher risk (OR,
2.56; 95% CI, 1.31e5.16) of having COPD than those homozygous for the A allele [35.8% (54/
151) vs. 24.0% (24/100); p Z 0.007]. Participants with the A allele of the Atg16L1 gene poly-
morphism (AA and AG genotypes) had a 3.34-fold higher risk (OR, 3.34; 95% CI, 1.32e8.97) oft of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng-Li Road, Tainan 704,
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Autophagy in COPD 751having COPD than those homozygous for the G allele [93.4% (141/151) vs. 81.0% (81/100);
p Z 0.013].
Conclusion: The Egr-1 and Atg16L1 genes’ polymorphisms were significant risk factors for sus-
ceptibility to COPD. These results demonstrate that autophagy regulator genetic mutations are
associated with COPD in male smokers.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is currently
the fourth leading cause of death worldwide, and the World
Health Organization estimates it will be the third leading
cause of death by 2020.1 Surprisingly, there are no effective
drug therapies for COPD able to significantly alter the dis-
ease’s progression, and little is known of the underlying
molecular mechanisms responsible for its occurrence.1
Further knowledge of the genetics of COPD may lead to
new treatments or to an increase in our understanding of
the disease’s pathogenesis.2 However, current knowledge
on the genetics of COPD is limited.
Autophagy (self-eating) is a lysosomal degradation
pathway that is essential for survival, differentiation,
development, and homeostasis. Autophagy has previously
been implicated in several human diseases including can-
cer, neurodegeneration, aging, and inflammatory bowel
disease.3 Recently, Chen et al4,5 demonstrated for the first
time that increased autophagy was associated with
increased cell death and contributes to COPD pathogenesis
by promoting epithelial cell death. They also demonstrated
a critical role for the early growth response-1 (Egr-1) gene
in promoting autophagy and aptosis in response to cigarette
smoke exposure in vitro and in vivo. Egr-1 is a zinc finger
transcription factor, classified as an immediate-early
response protein in human pulmonary epithelial cells.
Exposure to cigarette smoke extract (CSE) resulted in
rapidly induced autophagy by increasing the binding of Egr-
1 to the autophagy gene light chain-3B (LC3B) promoter,
increasing autophagic protein expression. In addition,
knockdown of Egr-1 inhibited the expression of autophagic
protein in Egr-1e/e mice, which displayed basal airspace
enlargement and resisted cigarette-smoke induced auto-
phagy and emphysema.4 An Egr-1 gene polymorphism
(e4071 A / G) had been associated with the serum IgE
level and atopy in Chinese asthmatic children,6 but its as-
sociation with COPD has not been explored. In addition,
previous studies demonstrated that loss of the autophagic
protein Atg16L1 enhanced endotoxin-induced inflammatory
cytokines.7 Genome-wide association studies have also
identified Atg16L1 (T300A) as a candidate gene responsible
for susceptibility to chronic inflammatory bowel disease.8,9
Our hypothesis is that genetic polymorphism in auto-
phagy regulator genes such as Egr-1 and Atg16L1 may be
linked to susceptibility to COPD. The aim of this study is to
explore the role of Egr-1 (e4071 A / G) and the Atg16L1
(T300A) gene in COPD. The genotypes of Egr-1 and Atg16L1
for patients with COPD and control individuals will be
evaluated by polymerase chain reaction (PCR) followed by
restriction fragment length polymorphism analysis. If weprove our hypothesis that autophagy regulator genetic
variation is associated with airflow obstruction in smokers,
we may be able to support the evidence of the role of
autophagy in the pathogenesis of COPD. This may present
an opportunity for the development of novel target thera-
pies for autophagy in COPD patients.
Patients and methods
Study population
This was a hospital-based, case-control study consisting of
251 participants. The case group included 151 men aged
40 years with smoking-related COPD (smoking history 10
packeyears) recruited from National Cheng-Kung University
Hospital. They were diagnosed as having COPD based on
their medical histories, chest radiographic findings, and
spirometric results, according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2008 guidelines.1
Inclusion criteria for COPD included the following: chronic
airway symptoms and signs such as coughing, dyspnea, and
wheezing, and chronic airway obstruction defined as a ratio
of the postbronchodilator forced expiratory volume in 1
second (FEV1)/forced vital capacity (FVC) of <70%. Patients
were excluded if they had a history of asthma. The severity
classification according to the GOLD stages1 for these 151
patients were mild (37/151; 24.5%), moderate (65/151;
43.1%), severe (34/151; 22.5%), and very severe (15/151;
9.9%).
The control group included 100 asymptomatic men 40
years of age (smoking history 10 packeyears) without
clinical symptoms of COPD and with normal pulmonary
function (FEV1/FVC 70% and FEV1 80% predicted). Most
of the control participants visited our hospital for health
checkups. We enrolled only men in this study because there
are very few women who smoke or have COPD in our
population.
The study was approved by the Ethics Committee of the
National Cheng-Kung University Medical College and Hos-
pital, and informed consents were obtained.
DNA extraction and polymerase chain reaction
restriction fragment length polymorphism
Genomic DNA was isolated using Puregene commercial DNA
isolation kits according to standard procedures (Gentra
Systems, Inc., Minneapolis, MN, USA). The total volume of
the PCR amplification mixture was 50 mL and contained
100 ng of genomic DNA, 0.5 mM of a dNTP Mix, 0.5 U Taq
DNA polymerase, 0.2 mM of each nucleotide, and 1.5 mM
Table 1 Patient characteristics of the COPD and control
group smokers.
COPD (n Z 151) Controls (n Z 100)
Age (y) 69.0  0.8 57.3  1.0
Smoking/packeyears 49.1  2.3 34.7  2.8
Current smokersa 63/144 (43.8) 65/97 (67.0)
FEV1 % predicted 55.1  1.5 98.6  1.9
FEV1/FVC ratio 50.6  0.8 78.0  0.9
Data are presented as mean  SD or n (%).
*All p values are <0.001.
COPD Z chronic obstructive pulmonary disease.
a Smoking status for seven patients and three controls was
unknown.
752 C.-Z. Chen et al.MgCl2. The amplification protocol was done using the Perkin
Elmer DNA Thermal Cycler 9600 (Perkin Elmer, Waltham,
MA, USA).
Two polymorphisms in the autophagy regulator genes: an
A to G polymorphism in Egr-1 (e4071 A / G; rs7729723)
and the polymorphism Atg16L1 (T300A) (rs2241880), an A to
G polymorphism resulting in the amino acid exchange at
position 300 of the protein (Thr300Ala), were genotyped
using PCR and restriction fragment length polymorphism
analysis according to the method of Chan et al6 and Cso¨ngei
et al.10 For the A to G polymorphism in Egr-1 (e4071
A / G), the primer sequences were 50-GTG ATT CTC ATT
GGC CTG GT-30 (sense) and 50-TAC TAT TCC CCA GCC AGC
AG-30 (antisense). For the Atg16L1 T300A, the primer se-
quences were 50-CTC TGT CAC CAT ATC AAG CGT GG-30
(sense) and 50-TCT AGA AGG ACA GGC TAT CA CAG ATG-30
(antisense). The fragments were separated by electropho-
resis through 3% agarose gel, stained with ethidium bromide
and transilluminated with ultraviolet light.Table 2 Association of the Egr-1 polymorphism (rs
7729723) with COPD.
Allele frequency
and polymorphism
COPD
(n Z 151)
Controls
(n Z 100)
OR (95% CI) pStatistical analysis
Descriptive statistics values are given as mean  standard
error and relative frequencies or absolute numbers. De-
viations from HardyeWeinberg equilibrium analysis were
performed using c2 tests with one degree of freedom. As-
sociations between specific genotypes and phenotypes
were analyzed for significance using logistic regression
model. Interaction was estimated by calculating odds ratios
(ORs) adjusted for age and cumulative cigarette consump-
tion in packeyears between the COPD and control groups.
Multivariate logistic regression analysis was used to assess
the contributions of the genetic factors to the risk of
developing COPD and progressive airflow limitations in all
smokers. Because only three (2%) patients and three (3%)
controls with the GG genotypes of Egr-1(e4071 A / G)
were noted, GG and GA genotypes were combined into a
single category for the statistical comparisons. We used the
JMP software program for multivariate analysis (SAS Insti-
tute, Inc. Cary, NC, USA). Power analysis was calculated
using Quanto version 1.2.4 (hydra.usc.edu/GxE/; 2009).
The genetic effects of the Egr-1 (e4071 A / G) poly-
morphisms were assumed to be G allele dominant and the
effects of the Atg16L1 (T300A) polymorphisms were
assumed to be A allele dominant. The population risk was
assumed to be 10%. Adjustment for multiple corrections
was made using the Bonferroni approach. In each analysis,
a difference with p < 0.05 was accepted as significant.Egr-1e4071
A 81.1 86.5 1 0.017
G 18.9 13.5 2.05
(1.15e3.72)
AA 97 (64.2) 76 (76.0) 1 0.007
AG and GGa 54 (35.8) 24 (24) 2.56
(1.31e5.16)
Data are presented as %, n (%), or n (range).
CI Z confidence interval; COPD Z chronic obstructive pulmo-
nary disease; OR Z odds ratio.
a Only three (2%) patients and three (3%) controls with the GG
genotypes, AG and GG genotypes were combined into a single
category for the statistical comparisons.Results
The characteristics of the control and COPD subjects are
summarized in Table 1. The mean age and smoking history
were lower in the control group than the COPD group; we
adjusted for this incomplete matching in the analysis of the
data. The HardyeWeinberg equilibrium was used to test the
genotypes for Egr-1 (e4071 A/ G) and Atg16L1 (T300A) in
both the COPD and control groups, and no obvious de-
viations were found (c2 < 3.84); the test results that pre-
sented as c2 were 1.60 and 0.98 for Egr-1 genotypes inCOPD and control groups, 1.01 and 3.75 for ATG16L1 ge-
notypes in COPD and control groups, respectively.
Participants with the G allele (GG and GA genotypes) of
the Egr-1(e4071 A / G) polymorphism had an increased
risk of developing COPD than those homozygous for the A
allele (OR, 2.56; 95% CI, 1.31e5.16). The frequency of the G
allele as a combined GG and GA genotype was significantly
higher in the COPD group than the control group [35.8% (54/
151) vs. 24.0% (24/100); pZ 0.007; Table 2]. The power to
detect genetic risks of 2.56 (OR) was 91.9% if the inheri-
tance mode was G allele dominant. No significant differ-
ence in the Egr-1 genotypes between the COPD and control
group was noted if the inheritance mode was G allele
recessive.
Subjects with the G allele (GG and GA genotypes) of the
Egr-1(e4071 A / G) polymorphism also had lower lung
function data (FEV1 % of prediction and ratio of FEV1/FVC)
than those homozygous for the A allele, but the difference
was not significant (69.4  3.0 % vs. 73.7  2.0 %, pZ 0.24
and 59.3  1.7 vs. 62.5  1.1; p Z 0.11, respectively).
Participants with the AA genotypes and AG genotypes of
Atg16L1 (T300A), both had an increased risk of developing
COPD than those homozygous for the G allele (OR, 3.64; 95%
CI, 1.35e10.50; pZ 0.013 and OR, 3.23; 95% CI, 1.18e9.48;
p Z 0.026 respectively, but the difference for AG vs. GG
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tion for multiple tests; Table 3). The A allele (combined AA
and AG genotypes) of the Atg16L1 (T300A) polymorphism
had an increased risk of developing COPD than those ho-
mozygous for the G allele [93.4% (141/151) vs. 81.0% (81/
100); OR, 3.34; 95% CI, 1.32e8.97; p Z 0.013]. The power
to detect genetic risks of 3.34 (OR) was 77.5% if the in-
heritance mode was A allele dominant. No significant dif-
ference in the Atg16L1 genotypes between the COPD and
control group was noted if the inheritance mode was A
allele recessive. Accordingly, individuals with the A allele
(combined AA and AG genotypes) of the Atg16L1 (T300A)
polymorphism had lower lung function than those homo-
zygous for the G allele (FEV1 % of prediction: 60.8  1.0 %
vs. 67.4  2.7 %, p Z 0.023 and ratio of FEV1/FVC:
70.9  1.8 % vs. 84.3  4.9 %, p Z 0.011). No significant
difference in the lung function data between the Atg16L1 G
allele (combined GG and GA genotypes) and homozygous
for the A allele was noted if the inheritance mode was A
allele recessive.
There was no significant difference between the severity
of airway obstruction (FEV1 % of prediction and ratio of
FEV1/FVC) and genotypes (Egr-1 of AA vs. AG þ GG and
Atg16L1 of AA þ AG vs. GG) in the COPD patients.
In the genetic models for the allele of Egr-1 (e4071
A/ G) polymorphism; the frequency of the G allele for the
Egr-1 polymorphism was higher in the COPD group than the
control group (57/302, 18.9% vs. 27/200, 13.5%; OR, 2.05;
95% CI, 1.15e3.72; p Z 0.017). In the genetic models for
the allele of the Atg16L1 (T300A) polymorphism, the fre-
quency of the A allele for the Atg16L1 polymorphism was
higher in the COPD group than the control group (215/302,
71.2% vs. 125/200, 62.5%; OR, 1.58; 95% CI, 1.02e2.47;
pZ 0.047), but the difference was not significant after the
Bonferroni correction for multiple tests.
The prevalence of the minor allele (G allele) of Egr-1 (rs
7729723) polymorphism in the single nucleotide poly-
morphism database (dbSNP) has been reported to range
from 15.9% to 25.6% in the Han Chinese populations (Asian).
The frequency of the G allele in the present study was
13.5% (27/200) within the control group, close to that re-
ported in the dbSNP. The prevalence of the minor allele (GTable 3 Association of the Atg16L1 polymorphism (rs
2241880) with COPD.
Allele frequency
and polymorphism
COPD
(n Z 151)
Controls
(n Z 100)
OR (95% CI) p
Atg16L1
A 71.2 62.5 1.58
(1.02e2.47)
0.047
G 28.8 37.5 1
AA 74 (49.0) 43 (43.0) 3.64
(1.35e10.50)
0.013
AG 67 (44.4) 38 (38.0) 3.23
(1.18e9.48)
0.026
GG 10 (6.6) 19 (19.0) 1
Data are presented as %, n (%), or n (range).
CI Z confidence interval; COPD Z chronic obstructive pulmo-
nary disease; OR Z odds ratio.allele) of Atg16L1 (rs 2241880) polymorphism in the dbSNP
has been reported to range from 23.8% to 39.0% in the Han
Chinese populations. The frequency of the G allele in the
present study was 38.0% (76/200) within the control group,
consistent with that reported in the dbSNP.Discussion
In the present study, a significant positive association be-
tween autophagy regulator gene mutation Egr-1 (e4071
A / G) and COPD was noted. Egr-1 has the capacity to
regulate genes relevant to the pathogenesis of COPD, such
as those related to matrix metalloproteinase expression
and remodeling, including the active airway obstruction
and fibrosis characteristic of the earlier course of emphy-
sema.11,12 Egr-1 has been characterized as an immediate
early response gene that is induced rapidly following
various cellular stresses including oxidative stress, an
important causative factor in COPD,13e15 and was sustained
induced in late-stage emphysema patients.11 Comprehen-
sive gene expression analyses have identified Egr-1 as a
gene whose expression changed significantly in COPD.12
Currently, there is no evidence that the Egr-1 genetic
polymorphism, which causes variability in the regulation of
autophagy, may determine individual susceptibility to COPD
in individuals carrying such polymorphisms. However, it is
possible considering the results of our study.
A significant association between autophagy-related
gene mutation Atg16L1 (T300A) and COPD was noted. The
Atg16L1 (T300A) polymorphism, which leads to the amino
acid exchange at position 300 of the protein (Thr300Ala) is
suggested to be functionally effective and is associated
with Crohn’s disease.8e10 Crohn’s disease is a chronic in-
flammatory bowel disease. Environmental risk factors such
as cigarette smoke and genetic factors such as a1-
antitrypsin deficiency affect the pathogenesis of both
COPD and Crohn’s disease.16 These studies suggest that
COPD and Crohn’s disease may have common inflammatory
pathways, including genetic variants in regulating auto-
phagy. This hypothesis was consistent with our findings. The
only difference was that in patients with Crohn’s disease,
the G allele was the risk allele of susceptibility for dis-
eases,8e10 whereas the A allele was the risk allele of sus-
ceptibility for COPD in the present study. Individuals with
the A allele carriers (AA and AG genotypes) of Atg16L1
(T300A) polymorphism have an increased risk of developing
COPD than those homozygous for the G allele (OR 3.34, 95%
CI: 1.32e8.97). The described result may be due to the fact
that autophagy can promote both cell survival and cell
death, depending on the different specific stimuli, envi-
ronmental conditions, and cell type.17 For example, psori-
asis is a chronic inflammatory disease of the skin,
inflammatory cytokines such as C-reactive protein, tumor
necrosis factor-a, interleukin-6, and interleukin-8 have
been found to be etiologically involved in both psoriasis and
COPD,18 an effect similar to the disease susceptibility in the
present study was noted in a previous study for psoriasis
vulgaris. The frequency of homozygous for the A allele for
Atg16L1 (T300A) was higher in the psoriasis group as
compared to the controls (36.5% vs. 27.8%),19 but the fre-
quency of homozygous for the A allele was significantly
754 C.-Z. Chen et al.decreased in Crohn’s disease as compared to the controls
(12.5% vs. 27.3%).20
The genetic polymorphisms for autophagy in the present
study were associated with the development of COPD, but
not with the spirometric severity of COPD. Inconsistent
results for the genetic predisposition of smokers to ac-
quired COPD and genetics bases of COPD severity with rapid
decline of FEV1 was also found in the matrix metal-
loproteinase; matrix metalloproteinase 9 polymorphisms
are associated with the development of smoking-induced
pulmonary emphysema, but not associated with a rapid
decline of lung function. This result may be due to COPD
susceptibility and progressive airflow limitations are
different clinical phenotypes associated with different
genes.2 Another possible reason was that spirometry is not
a suitable severity assessment tool in the present study.
Autophagy play a role in cigarette smoke induced emphy-
sema.8 COPD patients with emphysema were documented
by high-resolution computed tomography scan (HRCT) in
clinical practice; severity assessment by HRCT scan would
be a more informative evaluation rather than conventional
spirometry. Further studies for COPD patients using HRCT to
assess the association between autophagy gene poly-
morphism and COPD severity would provide stronger evi-
dence of the role of autophagy genes in disease
progression.
One limitation of the present study was that only men
were enrolled. The majority of patients with smoking-
related COPD in our population are men (smoking preva-
lence for women is <5%).21 In contrast to industrialized
countries in the West, COPD morbidity remains male pre-
dominant in Asian countries. 22The second limitation was
that this study was not replicated in an independent
cohort. The third limitation was that a relatively small
number of participants were recruited and the findings
were limited to the Chinese population. A large group of
study participants including various demographics should
be considered for future studies to clearly demonstrate a
significant contribution of these polymorphisms.
In conclusion, in our population, there were two genes
involved in autophagy. The Egr-1 and the Atg16L1 genes’
polymorphisms were significant risk factors for suscepti-
bility to smoking-related COPD. Autophagy can be phar-
macologically induced by inhibiting negative regulators
such as the target of rapamycin with rapamycin or inhibited
by targeting the class III P13K involved in autophagosome
formation.23 If further studies can confirm that loss of
function autophagy genetic mutations play a major role in
airflow obstruction in patients with COPD, possible thera-
pies can be developed to treat these patients. Further,
scientists can attempt some mechanism-based studies to
verify the functional significance of these polymorphisms in
context with various diseases in the future.
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